Brandworks Technologies Pvt. Ltd. is an electronics manufacturing company specializing in Charging Solutions, Home Audio, Surveillance & Monitoring, and Module Solutions. We also design and manufacture bike and car clusters, delivering innovative and reliable products across diverse electronic domains.
Boson Machines OPC Pvt Ltd
At Thee Packaging Company, we believe packaging is more than a container â itâs the first handshake between a brand and its customer. It carries not just a product but a promise: of quality, consistency, and a memorable customer experience.Based in Mumbai, India, Thee Packaging Company is one of the fastest-growing manufacturers and exporters of foodservice packaging solutions â proudly serving Quick Service Restaurants (QSRs), cafés, delivery platforms, and retail chains across India and international markets.What We Offer: Paper Bags⢠PTH Bags (Flat Handle, Twisted Handle)⢠SOS Kraft Bags⢠Oil & Grease Resistant (OGR) Bags â Coffee Cups⢠PE Coated Paper Cups⢠Aqueous Coated (Aqua) Paper Cups⢠PLA Compostable Cups⢠Ripple Wall, Single Wall, Double Wall Variants Soup Bowls⢠Leak-proof paper bowls for hot and liquid foods, with PE or compostable coatings PP Beverage Series⢠PP Sipper Cups⢠Juice and Cold Drink Cups⢠Injection Molded and Thermoformed Beverage Solutions Custom Mono Cartons⢠Printed retail-ready cartons for food, FMCG, and e-commerce applications Why Buyers Choose Thee Packaging Company:â Export-Ready:⢠End-to-end shipping support including documentation, customs paperwork, and on-time dispatches⢠Experience shipping to North America, Europe, and the Middle East â Global Standards & Certifications:⢠Food-grade compliant materials⢠Sustainable options including recyclable and compostable lines⢠Committed to globally recognized certifications for food safety and environmental standards â Customization Expertise:⢠Full-service custom printing, private label production, and branded packaging solutions⢠MOQ flexibility to support both growing brands and large rollouts â Consistent Quality at Scale:⢠Structured production systems and strong supply chain management⢠Quality assurance embedded at every stage â Sustainability that Performs:⢠Real solutions like OGR recyclable bags, compostable cups, and aqueous coatingsânot marketing greenwashOur Belief:Packaging isnât just about shipping products â itâs about delivering experiences. At Thee Packaging Company, we engineer packaging that protects quality, preserves brand perception, and scales effortlessly across fast-moving foodservice businesses.As we exhibit at the National Restaurant Association Show 2025 in Chicago, we are excited to meet foodservice operators, distributors, and brands looking for a trusted, export-ready packaging partner from India.Letâs build the future of food packaging, together.
BLEND COLOURS Pvt. Ltd.
Blend Colours is one of top manufacturer & Exporter of Plastic masterbatches from India, recognised as ‘two star export house’ by the government of india, our product range includes: white, black, color, additive masterbatches, mono concentrates for PE/PP/PET. Specialties like BioPlastics, Anti-Microbial, HFFR Compounds etc. Blend Colours exports have spread over 70+ countries including Europe, Africa, Latin & Central America, the Middle East and Asia, with approved quality and satisfied customers. | Blend is one of top manufacturer & Exporter of Plastic masterbatches from India, recognised as ‘two star export house’ by the government of india, our product range includes: white, black, color, additive masterbatches, mono concentrates for PE/PP/PET. Specialties like BioPlastics, Anti-Microbial, HFFR Compounds etc. Blend Colours exports have spread over 70+ countries including Europe, Africa, Latin & Central America, the Middle East and Asia, with approved quality and satisfied customers.
Bioxgreen Technology Pvt. Ltd.
Bioxgreen is launching BioActiv IFAS at WEFTEC 2025 in Chicago, USA. Visit us at stand 5479, South Building. BioActiv IFAS by Bioxgreen is an advanced attached growth technology for wastewater treatment, featuring pre-coated media with pollutant-specific microbial consortia for faster start-up and greater treatment efficiency. Performance and Benefits • Faster Startup: Shorter activation time compared to conventional IFAS, due to preformed biofilm. • Customizable: Media and consortia designed per effluent characteristics—ideal for industrial ETP brownfield upgrades. • Improved Process: Doubles efficiency and stabilizes plants in half the time of regular IFAS; includes aerobic, anaerobic, and anoxic zones for enhanced retention and nitrification. • Maintenance: Easy management by any trained operator, with booster and maintenance dosing protocol. • Lower Investment: Fewer pieces are required, reducing media and transport costs compared to floating PP/HDPE media. Please click on the link below for more technical details. https://www.perplexity.ai/search/b170a0d7-d7ac-4916-93e2-5face2ac7256
Biotechnology Industry Research Assistance Council (BIRAC)
Biotechnology Industry Research Assistance Council (BIRAC) is a not-for-profit, Public Sector Enterprise, set up by Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India. BIRAC/DBT as a central enabler, nurtures biotech innovation ecosystem in the country to address unmet needs in Healthcare, Agritech, Industrial Biotech and Clean Environment. BIRAC acts at the industry-academia interface and implements its mandate through a wide range of impact initiatives in public private partnerships mode that include providing risk capital through targeted funding, capacity building, common access infrastructure creation, nucleating a network of strategic partners with national & international stakeholders, policy advocacy, data analysis; leads National Missions like Startup India and Make In India for Biotech Sector. | Biotechnology Industry Research Assistance Council (BIRAC) is a not-for-profit Section 8, Schedule B, Public Sector Enterprise, set-up by Department of Biotechnology (DBT), Government of India has been spearheading the growth of the biotech innovation ecosystem in India as a central enabler. Over the last 12 years, BIRAC has supported innovations in varied areas of biotechnology and has worked aggressively on building pathways for entrepreneurial journeys through various focused initiatives, including funding, incubation, mentoring, and global networking. BIRAC has showcased its commitment and capabilities through tangible outcomes, fostering the growth of a biotech ecosystem that competes on a global scale. This has led to the advancement of numerous innovations into market-ready products and technologies, effectively tackling societal challenges. BIRAC operates several funding schemes for different stages of product/technology development. This includes : BioNEST (Bio-incubators Nurturing Entrepreneurship for Scaling Technologies) & E-YUVA (Empowering Youth for Undertaking Value Added) for creating a strong incubation network, BIG (Biotechnology Ignition Grant) as the largest early-stage funding for startups and entrepreneurs, BIPP (Biotechnology Industry Partnership Programme) & SBIRI (Small Business Innovation Research Initiative) for mid-late validation support for Startups, SMEs & large companies, PACE (Promoting Academic Research Conversion to Enterprise) for academic entrepreneurship, SPARSH (Social Innovation programme for Products Affordable & Relevant to Societal Health). BIRAC also provides equity funding through three of its schemes, namely, SEED (Sustainable Entrepreneurship and Enterprise Development), LEAP (Launching Entrepreneurial Driven Affordable Products), and the Fund of Funds, AcE (Accelerating Entrepreneurs) Fund. BIRAC’s Grand Challenges India (GCI) programme, in collaboration with the Bill & Melinda Gates Foundation, and the National Bio-Pharma Mission (NBM), in collaboration with the World Bank, are two major international co-funding partnerships. The mission of GCI is to foster innovation and research to develop affordable and sustainable solutions to improve health and well-being in India and around the world. The National Bio-Pharma Mission is an industry-academia collaborative mission for “accelerating discovery research to early development for biopharmaceuticals.” BIRAC schemes and programmes have helped create a network of 95 incubation and pre-incubation centers across the country, supported over 4000 beneficiaries, and enabled the development of over 800 biotech products that have reached the market. BIRAC – supported startups have raised substantial investments from private investors, providing a testimony to the potential that many of these startups hold for the future. BIRAC’s new initiative, Regulatory Affairs and Policy Advocacy (RAPA), aims at strengthening the regulatory and policy milieu of India. The “Ask Me Anything” platform “FIRST HUB” is the first of its kind single-window facilitation platform to address the queries of startups, entrepreneurs, researchers, academicians, incubation centers, SMEs, etc. BIRAC’s in-house IP & Technology Management group provides support to startups, institutes, academia, and SMEs on various aspects of IP & Technology Management, which include Patent Searches (Freedom-To-Operate, Patent landscape, Patentability search), facilitation of patent drafting & filing, Technology evaluation, and commercialization. BIRAC has forged partnerships with important national and global organizations to accomplish its vision and mission. These partnerships include both national and international organizations such as the World Bank, Bill & Melinda Gates Foundation (BMGF), Wellcome Trust, CEFIPRA, Business Finland, USAID, Vinnova – Sweden, Social Alpha, Tata Trust, WISH foundation, NESTA, CARB-X, TiE-Delhi NCR, ISBA, NASSCOM, UKRI, to name a few. BIRAC also works closely with other public agencies and governmental departments. India’s success in the COVID vaccine segment has been globally recognized and has made India proud. BIRAC played a significant role in implementing various COVID initiatives along with the Department of Biotechnology. Four indigenously developed COVID vaccines, namely, ZyCoV-D (World’s 1st and country’s indigenously developed DNA Vaccine), CORBEVAX™ (protein subunit vaccine), GEMCOVAC™ 19 (mRNA based vaccine), and iNCOVACC (intranasal COVID-19 Vaccine), have been validated through BIRAC support. BIRAC is playing a significant role in promoting “women entrepreneurship” in the country. More than 350 women-led startups and projects have been supported by BIRAC. Three incubation centers are dedicated specifically to women entrepreneurs. These include Golden Jubilee Biotech Park, Chennai, Sri Padmavati Mahila Visvavidyalayam, Tirupati, and PSGR Krishnammal College for Women, Coimbatore. National & International Contributions BIRAC also contributes to the Government’s national programs such as “Make in India,” “Startup India,” “Swachh Bharat,” and “Ayushman Bharat”. BIRAC has created a mega international-level showcasing event called the Global Bio India. GBI 2023 theme highlighted the potential and opportunities in ‘Biotech Innovation’ and ‘Bio-manufacturing’ and its impact on the Bioeconomy. The Mega event saw participation by over 5600 delegates, 25+ countries, 8 States representation promoting their Biotech policies. 1000+ B2B meetings took place. GBI 2024 would be held at Pragati Maidan, New Delhi from 12-14 September, 2024. BIRAC has been able to cultivate and expand the country’s biotech ecosystem through a holistic strategy involving tools such as product development support, advising, and mentoring startups in a variety of technological, IP, and business issues, developing, and operationalizing information-sharing networks, and establishing successful partnerships. BIRAC is working towards nurturing and empowering the startup community in India and the efforts have resulted in significant changes in landscape of Indian Biotechnology sector.
Bioneeds India Pvt. Ltd.
Bioneeds holds the esteemed reputation of being a OECD GLP, AAALAC, OLAW certified & USFDA-audited site recognized as one of the top preclinical CROs across the globe, with 250,000 sq ft built up space & 90+ in vivo experimental rooms. The team consists of 450+ professionals including Board certified toxicologists/pathologists, ERTs with rich industry experience. Our expertise spans a wide range of areas, including NCEs, Biologics, Vaccines, Generics, Medical devices, Agrochemicals, Industrial chemicals & others. Over the past 15+ years, we have worked closely with innovator companies, Generics, Biopharma etc.. & successfully facilitated submission of over 22,000 GLP studies to global regulatory bodies, with commitment to excellence, regulatory compliance & swift project execution. Bioneeds offers an array of services which includes General tox, DART, Inhalation, Genotox, Phys-chem, Ecotoxicology, ERA, Biocompatability, in vitro studies including analytical & bioanalytical, thus supporting end to end product development (IND/ANDA/NDA) for USFDA, EMA, WHO, Health Canada, ANVISA etc..& registrations (EPA/REACH). On the chemistry front, our expertise covers a wide spectrum of services for NCEs, Impurities & Intermediates. We have strong experience in multi-step synthesis of complex molecules and offer services such as impurity identification, Custom Synthesis & Process development. | Bioneeds holds the esteemed reputation of being a GLP, AAALAC, OLAW certified & USFDA-audited site recognized as one of the top preclinical CROs across the globe, with 250,000 sq ft built up space & 115+ in vivo experimental rooms. Our team consists of over 480 highly skilled professionals, including Board-certified toxicologists, pathologists, and ERTs with extensive industry experience. Our expertise spans a wide range of areas, including NCEs, Biologics, Monoclonal antibodies, ADC, Vaccines, Generics, Agrochemicals, Industrial chemicals & others. Over the past 16+ years, we have successfully facilitated submission of over 27500+ GLP studies to global regulatory bodies like USFDA, Health Canada, EMA.., with commitment to excellence, regulatory compliance & swift project execution. Bioneeds offers an array of services which includes General tox, DART, Inhalation, Environmental Risk Assessment (ERA), Genotox, Carcinogenicity, Neurotoxicity, Batch Release Studies, Phys-chem, Ecotoxicology, in vitro studies including analytical & bioanalytical, thus supporting end to end product development (IND/ANDA/NDA) & registrations (EPA/REACH). On the chemistry front, our expertise covers a wide spectrum of services for NCEs, Impurities & Intermediates. We have strong experience in multi-step synthesis of complex molecules and offer services such as impurity identification, Characterization, Custom Synthesis (5kg of non-GMP material) & Process development.
Biological E. Limited
Biological E. Limited (BioE), a Hyderabad-based Pharmaceuticals & Biologics Company founded in 1953, is the first private sector biological products company in India and the first pharmaceutical company in Southern India. BioE develops, manufactures and supplies vaccines and therapeutics. BioE supplies its vaccines to over 140 countries and its therapeutic products are sold in India and the USA. BioE has regulatory approvals from US FDA / EMEA and other major regulatory agencies across the globe for its vaccines/biologics and injectable facilities. BioE is a trusted CDMO partner, and is currently serving global clients as the largest and most advanced vaccine and biologics development and manufacturing hub. BioE offers a fully integrated service at a single site – a seamless solution that enables partners from clinical scale manufacturing, formulation development to commercial manufacturing. BioE understands the importance of delivering high-quality, safe, and effective vaccines to millions of people worldwide, and we work tirelessly to ensure that all of our processes meet or exceed the highest regulatory standards. BioE employs cutting-edge technologies, experts, teams of scientists, to deliver high-quality vaccines and therapeutics using state-of-the-art facilities. | Biological E Limited established in 1953, has a long and richly textured history in manufacturing and supplying vaccines to national immunization program as well as UNICEF and several countries around the world. BE has extensive experience in development / clinical & commercial manufacture of vaccines. BE vaccine portfolio includes 12 licensed vaccines, 9 of which are pre-qualified WHO vaccines, including SARS-CoV2 vaccine (CORBEVAX) licensed under the emergency vaccine list by WHO and 14-valent Pneumococcal conjugate vaccine (PCV-14) and nOPV2 under review by WHO prequalification. BE equipped with state-of-the-art R&D laboratories, manufacturing facilities, and more than 5,000 highly skilled employees, including 350 scientists. BE facilities are complying with rigorous compliance standards established by USFDA/EMEA/WHO/ANVISA Brazil/TGA Australia and other regulatory bodies. BE’s integrated services platform encompasses Microbial, Conjugate, Cell Culture, mRNA, Nanotechnologies (Liposome, Nanoparticles, Microemulsion), Peptides, Iron Colloidal, LMWH, Emulsion & Suspension. BE expertise in technology transfer, process development, and commercial manufacturing allows companies to assist clients at different stages of their journey. BE offers seamless End-to-End Contract Development and Manufacturing services for biologics spanning from process development to clinical and commercial GMP manufacturing of drug substance and drug product. BE’s aseptic fill/finish manufacturing capabilities include liquid & lyophilized platform technologies in Vial, Ampoule, PFS, Cartridge, Auto-injectors and multiple Drug-Device combination and Secondary Packaging. BE is the leading manufacture of vaccines and biopharmaceuticals. We look forward for in-licensing and co-development opportunities, which aid the company in accelerating the production of next-generation vaccines and RNA therapeutics. | Biological E. Limited (BE), established in 1953, is one of India’s pioneering and leading vaccine and biologics manufacturing companies. With over seven decades of experience, BE has been a trusted partner in global public health—supplying vaccines to national immunization programs, UNICEF, and over 140 countries worldwide. To date, BE has delivered more than five billion doses globally, making a significant impact on global health. BE’s robust vaccine portfolio includes 13 licensed vaccines, 11 of which are WHO pre-qualified, such as the CORBEVAX™ COVID-19 vaccine (listed under WHO’s Emergency Use Listing) and the 14-valent Pneumococcal Conjugate Vaccine (PCV-14), currently under WHO review for prequalification. Our state-of-the-art infrastructure includes cutting-edge R&D centers, GMP-compliant manufacturing facilities, and a strong workforce of over 5,000 skilled professionals, including 350+ scientists. BE’s facilities meet the highest global regulatory standards, including USFDA, EMEA, WHO, ANVISA (Brazil), and TGA (Australia), among others. BE’s integrated development and manufacturing platform spans a wide spectrum of technologies, including: • Microbial & Cell Culture Systems • Conjugate Vaccines • mRNA Platforms • Nanotechnologies (Liposomes, Nanoparticles, Microemulsions) • Peptides, LMWH, Iron Colloidal • Emulsions & Suspensions BE offers end-to-end solutions for biologics and vaccines, covering: • Process & Analytical Development • Clinical & Commercial GMP Manufacturing • Aseptic Fill-Finish capabilities (Liquid & Lyophilized) across Vials, Ampoules, PFS, Cartridges, Auto-injectors, and Drug-Device combinations • Secondary Packaging Our core strengths in technology transfer, co-development, and in-licensing enable us to bring innovative therapies to market faster—particularly in the areas of next-generation vaccines and RNA-based therapeutics. At BIO International Convention 2025, we are excited to explore meaningful collaborations and strategic partnerships. We look forward to connecting with potential partners who share our commitment to advancing global health.